



ALERT

NicOx: 2010 Financial Calendar

February 4, 2010. Sophia Antipolis, France. www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced the publication dates of its financial results in 2010. The financial results will be issued in a press release before the markets open according to the following schedule:

2009 full year results	4 March 2010
2010 first quarter results	7 May 2010
2010 second quarter and full semi-annual results	30 July 2010
2010 third quarter results	3 November 2010

The 2010 Financial calendar is available on the Company's website at www.nicox.com/update/financials.html

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

NicOx's lead investigational compound is naproxinod, an NCE and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate for the relief of the signs and symptoms of osteoarthritis. NicOx submitted a New Drug Application (NDA) for naproxinod to the US Food and Drug Administration (FDA) in September 2009 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in December 2009, following the successful completion of three pivotal phase 3 studies. The NDA for naproxinod was accepted for filing by the FDA in November 2009 and the FDA has set a target date of July 24, 2010, for the completion of its review. The MAA was validated by the EMA in January 2010.

In addition to naproxinod, NicOx's pipeline includes several nitric oxide-donating NCEs, which are in development internally and with partners, including Merck & Co., Inc., for the treatment of widespread eye diseases, cardiometabolic diseases, hypertension and dermatological disease.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).



CONTACTS: <http://www.nicox.com>

NicOx: Karl Hanks Director of Investor Relations and Corporate Communication
Tel +33 (0)4 97 24 53 42 • hanks@nicox.com

Media in the United States – FD Robert Stanislaro • Tel +1 212 850 5657 • robert.stanislaro@fd.com
Irma Gomez-Dib • Tel +1 212 850 5761 • irma.gomez-dib@fd.com

Media in Europe – Citigate Dewe Rogerson David Dible • Tel +44 (0)207 282 2949 • david.dible@citigatedr.co.uk
Nina Enegren • Tel +44 (0)207 282 1050 • nina.enegren@citigatedr.co.uk

NicOx S.A.,
Les Taissounières – Bât HB4 - 1681 route des Dolines - BP313 - 06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 •
Fax +33 (0)4 97 24 53 99